Sinco Pharmaceuticals Holdings Limited

Informe Stock SEHK:6833

Capitalización de mercado: HK$498.1m

Sinco Pharmaceuticals Holdings Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Sinco Pharmaceuticals Holdings ha aumentado sus ingresos a un ritmo medio anual de 59.1%, mientras que la industria Healthcare ha visto aumentar sus ingresos growing a 11.3% anualmente. Los ingresos han crecido growing a un ritmo medio anual de 20.7%. Sinco Pharmaceuticals Holdings La rentabilidad de los fondos propios de la empresa es de 4.5% y sus márgenes netos son de 1.2%.

Información clave

47.0%

Tasa de crecimiento de los beneficios

46.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare 11.3%
Tasa de crecimiento de los ingresos18.6%
Rentabilidad financiera6.7%
Margen neto1.7%
Última actualización de beneficios31 Dec 2023

Actualizaciones de resultados anteriores recientes

Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Apr 02
Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Recent updates

Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Apr 02
Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks

Mar 08
Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Nov 07
Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Jun 26
A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

May 30
Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

Oct 26
Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today

Feb 04
Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today

I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease

Oct 25
I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease

Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings

Jun 10
Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings

Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

May 24
Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock

Apr 20
Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock

We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings

Feb 16
We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings

How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 11
How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?

Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?

Dec 07
Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Sinco Pharmaceuticals Holdings. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

SEHK:6833 Ingresos, gastos y beneficios (CNY Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Dec 232,540422070
30 Sep 232,386351950
30 Jun 232,232271860
31 Mar 232,252481950
31 Dec 222,272692050
30 Sep 222,289962160
30 Jun 222,3071222320
31 Mar 222,1651282020
31 Dec 212,0241351720
30 Sep 212,1421481370
30 Jun 212,2611611020
31 Mar 212,1551401160
31 Dec 202,0501181300
30 Sep 201,664791500
30 Jun 201,277411700
31 Mar 201,227321660
31 Dec 191,176241620
30 Sep 191,045-972060
30 Jun 19915-2172510
31 Mar 19934-2492880
31 Dec 18953-2813250
30 Sep 18960-2422920
30 Jun 18966-2032580
31 Mar 18886-1952060
31 Dec 17807-1861530
30 Sep 17755-1151150
30 Jun 17704-43770
31 Mar 17781-12750
31 Dec 1685919740
30 Sep 1695836710
30 Jun 161,05752670
31 Mar 161,07661570
31 Dec 151,09670460
30 Sep 151,12077380
30 Jun 151,14484310
31 Mar 151,04777280
31 Dec 1495069240
31 Dec 1353237120

Ingresos de calidad: 6833 tiene ganancias de alta calidad.

Margen de beneficios creciente: 6833Los actuales márgenes de beneficio netos de (1.2%) son inferiores a los del año pasado (5.3%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 6833 se ha vuelto rentable en los últimos 5 años, con un crecimiento de los beneficios de 59.1% al año.

Acelerando crecimiento: 6833's ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: 6833 tuvo un crecimiento negativo de los beneficios (-77.7%) durante el año pasado, lo que dificulta la comparación con la media del sector Healthcare (-15.5%).


Rentabilidad financiera

Alto ROE: El Retorno sobre el capital de 6833 (4.5%) se considera bajo.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target